UPDATED: A little biotech crows about its Covid-19 'one and done' PhIII, causing at least one top analyst to change his tune as shares soar
The big heyday of market delirium related to anything positive in new Covid-related data has petered out as Omicron passes over, but little Eiger BioPharmaceuticals did get a quick pop-up in the stock price $EIGR this morning after reporting some upbeat results from its Phase III study of pegylated interferon lambda.
Eiger says it’s beating a path to the FDA to see about a snap emergency use authorization for its treatment after gathering late-stage data from close to 2,000 patients — 84% of whom had at least one vaccination against Covid.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.